摘要
目的探讨接受不同姑息性治疗后的肝门部胆管癌患者疗效及预后,以期为今后晚期肝门部胆管癌患者的姑息性治疗方法的选择提供帮助。方法选取2010年1月~2018年1月于安徽省立医院确诊为肝门部胆管癌的患者为研究对象,分析其术前相关检查数据以及手术相关资料。通过对患者电话随访了解其术后生存情况,分析三种姑息性减黄治疗的疗效以及预后。结果三种姑息性治疗减黄有效率比较、治疗后并发症发生率比较,三者之间差异均有统计学意义(P<0.05),其中姑息性手术治疗的减黄有效率最低,经内镜胆道支架引流减黄并发症发生率最低。接受姑息手术减黄治疗术后生存时间为(6.89±5.94)月,接受经内镜胆道支架引流减黄(ERCP)患者术后生存时间为(10.6±6.91)月,接受经皮肝穿刺胆道引流减黄(PTCD)患者术后生存时间为(7.2±5.86)月,三者比较差异有统计学意义。结论ERCP相对于PTCD与姑息手术对于晚期肝门部胆管癌具有较好的治疗效果,可作为晚期肝门部胆管癌患者减黄治疗的首选治疗方式。
Objective To investigate the efficacy and prognosis of patients with hilar cholangiocarcinoma after different palliative treatments,in order to provide help for the selection of palliative treatment methods for patients with advanced hilar cholangiocarcinoma in the future.Methods The patients with hilar cholangiocarcinoma diagnosed in Anhui Provincial Hospital from January 2010 to January 2018 were selected as the study subjects,and the preoperative examination data and surgical data were analyzed.Through telephone follow-up to understand the survival of patients after surgery,to analyze the efficacy and prognosis of three palliative yellow reduction treatments.Results There were significant differences among the three palliative treatments(P<0.05),including palliative surgery with the lowest effective rate and endoscopic biliary stent drainage with the lowest complication rate.The survival time after palliative surgery was 6.89(+5.94)months,after endoscopic biliary stent drainage(ERCP)was 10.6(+6.91)months,and after percutaneous transhepatic biliary drainage(PTCD)was 7.2(+5.86)months.There was significant difference among the three groups.Conclusion ERCP has a better therapeutic effect on advanced hilar cholangiocarcinoma than PTCD and palliative surgery.ERCP can be used as the preferred treatment for patients with advanced hilar cholangiocarcinoma.
作者
陈三韦
黄强
CHEN San-wei;HUANG Qiang(The Hospital of USTC,Hefei 230001,China)
出处
《肝胆外科杂志》
2020年第1期13-16,共4页
Journal of Hepatobiliary Surgery
